AbbVie (ABBV) Tops Q1 EPS by 1c; Updates FY16 EPS Outlook

AbbVie (NYSE: ABBV) reported Q1 EPS of $1.15, $0.01 better than the analyst estimate of $1.14. Revenue for the quarter came in at $5.96 billion versus the consensus estimate of $6.03 billion.

GUIDANCE:

AbbVie sees FY2016 EPS of $4.62-$4.82, versus the consensus of $4.97.

The company's 2016 adjusted diluted earnings-per-share guidance excludes $0.75 per share of intangible asset amortization expense, the impact of the Venezuelan currency devaluation, and other specified items. Including these items, AbbVie's diluted earnings-per-share guidance is $3.87 to $4.07 on a GAAP basis.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• EU approves AbbVie's Skyrizi for children with plaque psoriasis